Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Neuropharmacology. 2013 Apr 12;71:191–203. doi: 10.1016/j.neuropharm.2013.03.038

Fig. 6.

Fig. 6

TC-8831 decreased L-dopa-induced AIMs. The treatment regimen, depicted in the upper panel, shows that all rats were unilaterally lesioned with 6-OHDA. This was followed by pretreatment with TC-8831 (0.75 mg/kg/d) for 2 wk via minipump and subsequent injection with L-dopa plus benserazide (6.0 mg/kg plus 15 mg/kg sc). After several wk at 0.75 mg/kg/d TC-8831, the initial minipump was replaced with one releasing 0.3 mg/kg/d. Rats were rated for axial, oral and forelimb AIMs as indicated in the timeline, with the total AIMs being the sum of these three components. The daily time course of total L-dopa-induced AIMs is provided in the graphs at the right. Values are the mean ± S.E.M. of 10–13 rats per group. Significance of difference from vehicle: *p < 0.05, **p < 0.01, ***p < 0.001.